参考文献/References:
[1] 周自强,胡大一,陈捷,等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志,2004,43(7): 15-18.
[2] Lévy S,Maarek M,Coumel P,et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists[J]. Circulation,1999, 99(23):3028-3035.
[3] Huxley RR,Alonso A,Lopez FL,et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation:the Atherosclerosis Risk in Communities study[J]. Heart,2012,98(2):133-138.
[4] Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J,2016,37(38):2893-2962.
[5] Pallisgaard JL,Lindhardt TB,Olesen JB,et al. Management and prognosis of atrial fibrillation in the diabetic patient[J]. Expert Rev Cardiovasc Ther,2015,13(6):643-651.
[6] Dahlqvist S,Rosengren A,Gudbj?rnsdottir S,et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population:a prospective case-control study[J]. Lancet Diabetes Endocrinol,2017,5(10):799-807.
[7] Pallisgaard JL,Schjerning AM,Lindhardt TB,et al. Risk of atrial fibrillation in diabetes mellitus:a nationwide cohort study[J]. Eur J Prev Cardiol,2016,23(6):621-627.
[8] Benjamin EJ,Levy D,Vaziri SM,et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study[J]. JAMA,1994,271(11):840-844.
[9] Bohne LJ,Johnson D,Rose RA,et al. The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights[J]. Front Physiol,2019,10:135.
[10] Sanghai SR,Sardana M,Hansra B,et al. Indexed left atrial adipose tissue area is associated with severity of atrial fibrillation and atrial fibrillation recurrence among patients undergoing catheter ablation[J]. Front Cardiovasc Med,2018,5:76.
[11] Nagy E,Jermendy AL,Merkely B,et al. Clinical importance of epicardial adipose tissue[J]. Arch Med Sci,2017,13(4):864-874.
[12] Liu C,Liu R,Fu H,et al. Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits[J]. Cardiovasc Ther,2017,35(5).DOI:10.1111/1755-5922.12284.
[13] Zhang Y,Welzig CM,Picard KL,et al. Glycogen synthase kinase-3beta inhibition ameliorates cardiac parasympathetic dysfunction in type 1 diabetic Akita mice[J]. Diabetes,2014,63(6):2097-2113.
[14] Yi F,Ling TY,Lu T,et al. Down-regulation of the small conductance calcium-activated potassium channels in diabetic mouse atria[J]. J Biol Chem,2015,290(11):7016-7026.
[15] Skibsbye L,Poulet C,Diness JG,et al. Small-conductance calcium-activated potassium(SK) channels contribute to action potential repolarization in human atria[J]. Cardiovasc Res,2014,103(1):156-167.
[16] Serban RC,Scridon A. Data linking diabetes mellitus and atrial fibrillation—how strong is the evidence? from epidemiology and pathophysiology to therapeutic implications[J]. Can J Cardiol,2018,34(11):1492-1502.
[17] Bell DSH,Goncalves E. Atrial fibrillation and type 2 diabetes:prevalence, etiology, pathophysiology and effect of anti-diabetic therapies[J]. Diabetes Obes Metab,2019,21(2):210-217.
[18] Whisnant JP,Wiebers DO,O’fallon WM,et al. A population-based model of risk factors for ischemic stroke:Rochester, Minnesota[J]. Neurology,1996,47(6):1420-1428.
[19] Itzhaki Ben Zadok O,Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus[J]. Diabet Med,2018,35(5):548-556.
[20] Wang TJ,Massaro JM,Levy D,et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community:the Framingham Heart Study[J]. JAMA,2003,290(8):1049-1056.
[21] Fangel MV,Nielsen PB,Kristensen JK,et al. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus[J]. Circ Arrhythm Electrophysiol,2019,12(5):e007030.
[22] Hylek EM,Held C,Alexander JH,et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin:the aristotle trial(apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation):predictors,characteristics,and clinical outcomes[J]. J Am Coll Cardiol,2014,63(20):2141-2147.
[23] Zhang Z,Zhai Z,Yang Y,et al. Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy:findings from a "real-world" study[J]. J Thromb Thrombolysis,2017,43(4):540-549.
[24] Sohal AS,Gangji AS,Crowther MA,et al. Uremic bleeding: pathophysiology and clinical risk factors[J]. Thromb Res,2006,118(3):417-422.
[25] Lip G,Freedman B,de Caterina R,et al. Stroke prevention in atrial fibrillation:past,present and future. Comparing the guidelines and practical decision-making[J]. Thromb Haemost,2017,117(7):1230-1239.
[26] Hart RG,Pearce LA,Aguilar MI. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med,2007,146(12):857-867.
[27] Coleman CI,Bunz TJ,Eriksson D,et al. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes:an administrative claims database analysis[J]. Diabet Med,2018,35(8):1105-1110.
[28] Brambatti M,Darius H,Oldgren J,et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation:results from the RE-LY trial[J]. Int J Cardiol,2015,196:127-131.
[29] Budzianowski J,Hiczkiewicz J,Burchardt P,et al. Predictors of atrial fibrillation early recurrence following cryoballoon ablation of pulmonary veins using statistical assessment and machine learning algorithms[J]. Heart Vessels,2019,34(2):352-359.
[30] Akkaya E,Berkowitsch A,Zaltsberg S,et al. Five-year outcome and predictors of success after second-generation cryoballoon ablation for treatment of symptomatic atrial fibrillation[J]. Int J Cardiol,2018,266:106-111.
[31] Anselmino M,Matta M,D’ascenzo F,et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus:a systematic review and meta-analysis[J]. Europace,2015,17(10):1518-1525.
[32] Litwinowicz R,Bartus M,Ceranowicz P,et al. Left atrial appendage occlusion for stroke prevention in diabetes mellitus patients with atrial fibrillation:long-term results[J]. J Diabetes,2019,11(1):75-82.
[33] Chang SH,Wu LS,Chiou MJ,et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies[J]. Cardiovasc Diabetol,2014,13:123.
[34] Pallisgaard JL,Lindhardt TB,Staerk L,et al. Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study[J]. Eur Heart J Cardiovasc Pharmacother,2017,3(3):140-146.
[35] Pallisgaard JL,Brooks MM,Chaitman BR,et al. Thiazolidinediones and risk of atrial fibrillation among patients with diabetes and coronary disease[J]. Am J Med,2018,131(7):805-812.
[36] Chen HY,Yang FY,Jong GP,et al. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients[J]. Eur J Clin Invest,2017,47(5):388-393.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]张若愚,综述,殷跃辉,等.2型糖尿病及其药物对心房颤动的影响[J].心血管病学进展,2016,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
[8]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[11]高婧晗 刘飞 杨晓蕾 夏云龙.钙离子稳态的调控在糖尿病相关心房颤动中的作用[J].心血管病学进展,2021,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
GAO Jinghan,LIU Fei,YANG Xiaolei,et al.Regulation of Calcium Homeostasis in Diabetes-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(1):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]